HCC CONNECT has summarised the highlights from ESMO 2018 for you
Hepatocellular carcinoma by Dr. Changhoon Yoo, Asan Medical Center, University of Ulsan College of Medicine, Korea
Dr Changhoon Yoo is a medical oncologist who specialises in the care of patients with gastrointestinal cancers including hepatocellular carcinoma. He is an Assistant Professor at Asan Medical Center in Seoul, South Korea. Dr Yoo obtained his medical degree at the University of Ulsan College of Medicine, Seoul, South Korea and completed post graduate training at Asan Medical Center. He has participated in multiple clinical trials and translational research for the development of novel agents for patients with hepatocellular carcinoma. His research initiatives include the integration of novel targeted and immune-based therapy into the treatment of hepatocellular carcinoma. Relevant publications Kim HD, Song GW, Park S, Jung MK, Kim MH, Kang HJ, Yoo C, Yi K, Kim KH, Eo S, Moon DB, Hong SM, Ju YS, Shin EC, Hwang S, Park SH. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. Gastroenterology 2018 Aug 23; pii: S0016-5085(18)34897-2. doi: 10.1053/j.gastro.2018.08.030. [Epub ahead of print] PMID: 30145359 Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat 2018 Jun 13. doi: 10.4143/crt.2018.226. [Epub ahead of print] PMID: 29898591 Chae H, Cho H, Yoo C, Kim KP, Jeong JH, Chang HM, Kang J, Lee HC, Lim YS, Kim KM, Shim JH, Lee SS, Park DH, Song TJ, Hwang S, Song GW, Moon DB, Lee YJ, Lee JH, Ryoo BY. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. Int J Biol Markers 2018 Jun 1:1724600818777239. doi: 10.1177/1724600818777239. [Epub ahead of print] PMID: 29874985 Cho H, Yoo C, Kim KP, Jeong JH, Kang J, Chang HM, Lee SS, Park DH, Song TJ, Lee SK, Kim MH, Lee HC, Lim YS, Kim KM, Shim JH, Hwang S, Song GW, Moon DB, Lee JH, Lee YJ, Ryoo BY. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. Invest New Drugs 2018 Jun;36(3):496-502. doi: 10.1007/s10637-017-0548-7. Epub 2017 Dec 1. PMID: 29192354 Yoo C, Kang J, Kim D, Kim KP, Ryoo BY, Hong SM, Hwang JJ, Jeong SY, Hwang S, Kim KH, Lee YJ, Hoeflich KP, Schmidt-Kittler O, Miller S, Choi EK. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. Oncotarget 2017 Jun 13;8(24):38592-38601. doi: 10.18632/oncotarget.16951.
Asst. Prof. Changhoon Yoo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Bayer, Eisai, MSD, Ono and Ipsen.
HCC CONNECT Update from ESMO 2019
HCC CONNECT has summarised highlights of the recent ESMO 2019 meeting for you
Experts
Dr Su Pin Choo-
Downloadable
Resouces -
5 MIN
-
Sep 2021 -
HCC CONNECT Update from ILCA and ESMO 2020
HCC CONNECT has summarised the highlights from ILCA and ESMO 2020 for you.Liver Cancer update by Dr. Su Pin Choo, Curie Oncology and National Cancer Centre, Singapore
Experts
Dr Su Pin Choo-
Downloadable
Resouces -
5 MIN
-
Sep 2021
-
Programme summary
Duration 5 MIN
Downloadable resources Yes-
Download the slides
-
Language(s)
Share this programme
Brought to you by
HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.
Meet the experts
Other programmes of interest
Video
Oncology
Recent advances in precision oncology and future implications
Two emerging and two established targets
Experts
Prof. David Hong-
Downloadable
Resources -
4 MIN
-
Dec 2024
Publication
Oncology
Survey on the evolving role of the oncology nurse in the USA
Announcing the publication of survey results
Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo-
Downloadable
Resources -
10 MIN
-
Dec 2024
Video
Oncology
Elacestrant in ER+/HER2- metastatic breast cancer
An expert overview of the EMERALD subgroup analysis
Experts
Dr Virginia Kaklamani-
Downloadable
Resources -
4 MIN
-
Dec 2024
Video
Oncology
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)
Managing patients with nccRCC: guidelines, recommendations, and best practice
Experts
Prof. Laurence AlbigesEndorsed by
-
Downloadable
Resources -
4 MIN
-
Dec 2024
Micro learning
Oncology
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment
Risk factors, diagnostic tools and treatment options for different patient groups
Experts
Prof. Efrat Dotan, Prof. Shubham PantEndorsed by
-
Downloadable
Resources -
4 MIN
-
Dec 2024
Conference update
Oncology
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update
Exploring emerging treatment strategies presented at SABCS 2024
Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava-
Downloadable
Resources -
5 MIN
-
Dec 2024
